Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab versus interferon-gamma plus vitamin C versus routine care in critically ill COVID-19 patients
IRCT20200525047570N1Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tocilizumab, interferon gamma-1b and ascorbic acid in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Serum ferritin, Lactate dehydrogenase and 6 more. Started Jul 2020; status: completed.
02
Drugs
tocilizumabinterferon gamma-1bascorbic acid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200525047570N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200525047570N1.